Grand challenges in modulating the immune response with RNAi nanomedicines

Meir Goldsmith, Shoshy Mizrahy, Dan Peer

Research output: Contribution to journalReview article

31 Scopus citations

Abstract

RNAi is a ubiquitous and highly specific, endogenous, evolutionarily conserved mechanism of gene silencing. RNAi holds great promise as a novel therapeutic modality. Despite the rapid progress in the understanding and utilization of RNAi in vitro, the application of RNAi in vivo has been met with great difficulties, mainly in the delivery of these molecules into specific cell types. Here, we describe the major systemic nanomedicine platforms that have been developed. Focus is given to the development of new strategies to target subsets of leukocytes, which are among the most difficult cells to transduce with RNAi. Finally, we discuss the hurdles and potential opportunities for in vivo manipulation of the immune response utilizing RNAi nanomedicines.

Original languageEnglish (US)
Pages (from-to)1771-1785
Number of pages15
JournalNanomedicine
Volume6
Issue number10
DOIs
StatePublished - Dec 2011

Keywords

  • immune response
  • leukocytes
  • liposomes
  • nanomedicine
  • RNAi

ASJC Scopus subject areas

  • Materials Science(all)
  • Bioengineering
  • Biomedical Engineering
  • Medicine (miscellaneous)
  • Development

Fingerprint Dive into the research topics of 'Grand challenges in modulating the immune response with RNAi nanomedicines'. Together they form a unique fingerprint.

Cite this